VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?